The likely royalty stream to BTA should increase to ~$120M pa as GSK ramps up production, or ~90cps. Combined with the dual relenza molecule in advanced testing, the current share price looks a touch underdone. Surely within a year or less the likely fast-tracked license deals, perhaps $150M penalty payment from an obviously derelict GSK, the existing FluOIA diagnostic test and pipeline projects should make the true value of BTA closer to $25 than $1.
On a personal note, hope you can (also) get some relenza for personal use (it is still possible if you know where to look).
BTA Price at posting:
0.0¢ Sentiment: ST Buy Disclosure: Held
HotCopper & The Market Online will be live From the Floor at the Mining News Select Conference and we want to bring the voice of our online audience to the show with us.